SUO 4001
Alternative Names: SUO-4001Latest Information Update: 31 Oct 2023
At a glance
- Originator Suono Bio
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Crohn's disease
Most Recent Events
- 17 Oct 2023 SUO 4001 is available for licensing as of 17 Oct 2023. https://www.suonobio.com/work-with-us.html
- 17 Oct 2023 Early research in Crohn's disease in USA (PO), prior to October 2023 (Suono Bio pipeline, October 2023)